Shuttle Pharma licenses predictive biomarker IP from Georgetown for prostate cancer RT

Shuttle Pharmaceuticals Holdings, Inc.

Exclusive license for patent application 17/476,184 ("Predictive Biomarkers for Adverse Effects of Radiation Therapy") from Georgetown University.
Upfront payment, maintenance fees, and milestone payments tied to validation trial, FDA approval, and commercial sales; 5% earned royalty on net sales.
IP developed by CEO Dr. Anatoly Dritschilo, Principal Scientist Dr. Scott Grindrod, and Georgetown researchers.
Company completed Phase I/II NIH SBIR contracts for the biomarker program; plans to seek Phase IIb SBIR bridge funding.
Program targets a blood test to predict radiation therapy outcomes for ~66,000 prostate cancer patients annually in the US.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Shuttle Pharmaceuticals Holdings, Inc. entered into License Agreement with Georgetown University (effective 2023-10-24).

Action: entry
Agreement: license
Counterparty: Georgetown University
Effective: 2023-10-24

Exact text from the filing

On October 24, 2023, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an exclusive licensing agreement (the “License Agreement”) with Georgetown University (“Georgetown”) pursuant to which Georgetown agreed to license the intellectual property known as “Predictive Biomarkers for Adverse Effects of Radiation Therapy” (U.S. Patent Application No. 17/476,184, filed on September 15, 2021) (the “Patent Rights”)

View on SEC.gov

114 material agreements filed in the last 30 days. Browse all material agreements →

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-038736

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.